This whitepaper provides a clear and concise overview of the Act’s background, intent, and the key pieces of regulatory legislation it is set to influence.
This article focuses on the impact of this EU pharma legislation reform with regards to orphan medicinal products.
Linnea Brodin
Finance Manager
BSc Business and Economics
Linnea is our Finance Manager. She has a BSc in Business and Economics from Södertörns University and has previously worked in the accounts payable department at Huddinge Kommun.
Staffan Thunell
Founding partner
BSc Economics and BA
Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from positions as Founder, Chairman, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.